NFO Opens in:
mailtimers.com mailtimers.com

Why Invest in the Healthcare Sector?

  • Healthcare is no longer just about hospitals or medicines. It’s now a fast-growing ecosystem that includes diagnostics, wellness and nutrition, biotechnology, analytics, medical equipment, health-tech, and more, all scaling up to meet rising demand.
  • India’s ageing population and rising income levels are driving steady, long-term demand.
  • The sector has grown at a 16% CAGR (2008–2023) to reach USD 372 billion, yet per-capita spending remains low, leaving ample room for potential future growth.
  • For investors, that makes healthcare a strong structural growth opportunity.
Low Volatility
#Source: IBEF, BSE, Make in India, Department of Pharmaceuticals.
Invest Now

Why Bandhan Healthcare Fund?

Balanced Portfolio Across
Four Healthcare Themes

Read more

Bottom-Up
Precision

Read more

Disciplined Stock
Selection

Read more

#1 Balanced Portfolio Across Four Healthcare Themes

Diversified exposure with core allocation (20–30% each) across Hospitals & Diagnostics, Export CDMO/API, Export Generics, and Domestic Branded Formulations##.

##CDMO: Contract Development and Manufacturing Organization; API: Active Pharmaceutical Ingredient
Invest Now

#2 Bottom-Up Precision

Segment-specific research across the four focus themes, assessing therapy growth, capacity expansion, innovation pipelines, pricing environment, regulatory track record, and brand strength to identify high-quality opportunities.

Icon1

Domestic Branded Formulations

  • +Higher share of faster-growing therapy areas
  • +Strong track record of market share gains
  • +Lower regulatory risk
Icon1

Hospitals & Diagnostics

  • +Favourable regional demand–supply dynamics
  • +Strong pipeline for capacity expansion
  • +Robust brand recall
Icon1

Export CDMO API

  • +High share of sales to innovators
  • +Robust pipeline across clinical stages (Phases 1–3) and commercial molecules
  • +Clear visibility on capacity expansion and upcoming capex
Icon1

Export Generics

  • +Demand–supply and pricing dynamics of products
  • +Regulatory inspection record of facilities
  • +Strong history of ANDA approvals and product launches
Note: ANDA: Abbreviated New Drug Application, CDMO: Contract Development and Manufacturing Organization.
API: Active Pharmaceutical Ingredient

#3 Disciplined Stock Selection

A research-driven approach guided by valuation comfort, ROCE, management quality, and sustainable growth potential.

table image
Note: ROCE stands for Return on Capital Employed
Invest Now

Looking to learn more about the fund?

Watch our explainer videos in your preferred language.

English

Hindi

Gujarati

Bengali

Consider investing in this fund if…

You seek exposure to a high-potential growth sector driven by long-term trends such as ageing populations, chronic diseases, and expanding access.

You want to diversify with a thematic strategy that offers both growth potential and defensive characteristics.

You are comfortable with short-term volatility in pursuit of potentially higher long-term returns compared to broad-market funds.

Downloads

Make an informed decision. Learn more about investing in Bandhan Healthcare Fund

Fund Facts

Type of Scheme

An open-ended equity scheme investing in healthcare, pharma and allied services

NFO Period

10th November to 24th November 2025

Benchmark

BSE Healthcare TRI

Fund Managers

Mr. Viraj Kulkarni & Mr. Brijesh Shah

Minimum Investment

During New Fund Offer
₹ 1,000
And in multiples of Re. 1 thereafter

Exit Load

If redeemed / switched out on / within 30 days from the date of allotment: 0.50% of the applicable NAV
If redeemed / switched out after 30 days from date of allotment – Nil

Plans/Options

Regular/Direct Plan: Growth Option

Investment Objective

The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.

Disclaimer: There is no assurance or guarantee that the scheme’s objectives will be realized.

Fund Managers

Abhishek Jain

Mr. Viraj Kulkarni

Vice President – Equities
Bandhan AMC Limited
September 2015 to date

Mr. Viraj Kulkarni serves as a Senior Analyst and Fund Manager in the Equity Fund management team at Bandhan AMC. With a focus on sectors such as IT Services, Cement, and Building materials, he brings nearly a decade of sector- specific expertise and insights.

Prior to joining Bandhan AMC, Mr. Kulkarni was associated with Franklin Templeton from May 2014 to September 2015 and had a tenure at Goldman Sachs from 2010 to 2012.

His educational credentials include a Post Graduate Diploma in Management (PGDM), a Chartered Financial Analyst (CFA) certification, and a B. Tech degree in Electrical & Electronics.

Abhishek Jain

Mr. Brijesh Shah

Senior Vice President – Fixed Income
Bandhan AMC Limited
August 2015 to date

Mr. Brijesh Shah currently holds the position of Senior Vice President – Fixed Income at Bandhan AMC. With a career spanning over 15 years in the fixed- income arena, Mr. Shah has accumulated extensive experience and expertise in this field.

Before his tenure at Bandhan AMC, he served at IDBI and Indiabulls AMC. In these roles, as a Senior Manager, he led the dealing function and was responsible for the execution of a variety of fixed-income instruments.

Mr. Shah is a postgraduate in Finance from the MET Institute of Management, Mumbai, and holds a Bachelor's Degree in Commerce from Mithibai College of Commerce and Economics.

Apart from his professional accomplishments, Mr. Shah is a founding member of Shasan-Setu, an organization dedicated to societal service. Beyond work, he nurtures a passion for the arts and has participated in cultural plays and short films.

Product info

Bandhan Healthcare Fund

(An open-ended equity scheme investing in healthcare, pharma and allied services)

This product is suitable for investors who are seeking*:

  • To create wealth over a long term.
  • Investment predominantly in equity and equity related instruments of pharma, healthcare and allied companies.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

riskometer